McBreen Michael J.
Known title: EVP & President, CSSCIK: 0001814943
Associated companies
Transaction History
| IART | ▼ Sell | Tax Withholding | 7,247 | $70K | 3/11/2026 | View on chart |
| IART | ▼ Sell | Tax Withholding | 2,354 | $22K | 3/10/2026 | View on chart |
| IART | ▼ Sell | Tax Withholding | 446 | $11K | 3/11/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,587 | $38K | 3/11/2025 | View on chart |
| IART | ▲ Buy | Grant | 18,480 | $0 | 3/11/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,229 | $28K | 3/10/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,056 | $24K | 3/10/2025 | View on chart |
| IART | ▼ Sell | Open Market | 1,700 | $41K | 12/2/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,572 | $56K | 3/12/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 440 | $16K | 3/12/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 492 | $18K | 3/11/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 3,430 | $124K | 3/11/2024 | View on chart |
| IART | ▲ Buy | Grant | 12,220 | $0 | 3/11/2024 | View on chart |
| IART | ▲ Buy | Grant | 8,283 | $0 | 3/11/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,457 | $54K | 3/10/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,198 | $44K | 3/10/2024 | View on chart |
| IART | ▲ Buy | Grant | 3,516 | $0 | 2/20/2024 | View on chart |
| IART | ▼ Sell | Tax Withholding | 655 | $34K | 3/13/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 298 | $16K | 3/13/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 751 | $40K | 3/12/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 451 | $24K | 3/12/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 427 | $23K | 3/12/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 857 | $45K | 3/11/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 491 | $26K | 3/11/2023 | View on chart |
| IART | ▲ Buy | Grant | 9,458 | $0 | 3/10/2023 | View on chart |
| IART | ▲ Buy | Grant | 8,128 | $0 | 3/10/2023 | View on chart |
| IART | ▼ Sell | Open Market | 1,843 | $100K | 3/7/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 723 | $40K | 3/2/2023 | View on chart |
| IART | ▲ Buy | Grant | 1,466 | $0 | 2/13/2023 | View on chart |
| IART | ▲ Buy | Grant | 1,008 | $0 | 2/13/2023 | View on chart |
| IART | ▲ Buy | Grant | 1,680 | $0 | 2/13/2023 | View on chart |
| IART | ▲ Buy | Grant | 1,919 | $0 | 2/13/2023 | View on chart |
| IART | ▼ Sell | Tax Withholding | 599 | $34K | 8/1/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 174 | $11K | 3/13/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 289 | $19K | 3/13/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 651 | $42K | 3/13/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,083 | $71K | 3/13/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 376 | $24K | 3/12/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 1,133 | $74K | 3/12/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 679 | $44K | 3/12/2022 | View on chart |
| IART | ▲ Buy | Grant | 3,332 | $0 | 3/11/2022 | View on chart |
| IART | ▲ Buy | Grant | 7,680 | $0 | 3/11/2022 | View on chart |
| IART | ▼ Sell | Tax Withholding | 466 | $31K | 3/2/2022 | View on chart |
| IART | ▲ Buy | Grant | 1,458 | $0 | 2/11/2022 | View on chart |
| IART | ▲ Buy | Grant | 2,424 | $0 | 2/11/2022 | View on chart |
| IART | ▲ Buy | Grant | 6,108 | $0 | 2/11/2022 | View on chart |
| IART | ▼ Sell | Open Market | 3,450 | $247K | 11/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
IART May Be 48% Undervalued Based on Cash Flow Analysis
A recent Yahoo analysis suggests Integra LifeSciences shares could be trading about 48% below their intrinsic value when cash flow is considered. The stock sits near its 13‑touch support level of $9.10 and an RSI of 41.6, indicating neither overbought nor oversold conditions. The average analyst target is $19.56, well above the current price, highlighting a potential valuation gap. This analysis may prompt a closer look at the company’s cash flow performance relative to market expectations.
IART May Be 48% Undervalued Based on Cash Flow Analysis. A recent Yahoo analysis suggests Integra LifeSciences shares could be trading about 48% below their intrinsic value when cash flow is considered. The stock sits near its 13‑touch support level of $9.10 and an RSI of 41.6, indicating neither overbought nor oversold conditions. The average analyst target is $19.56, well above the current price, highlighting a potential valuation gap. This analysis may prompt a closer look at the company’s cash flow performance relative to market expectations.